Johnson & Johnson has announced its expansion in North Carolina. The company plans to establish a dedicated manufacturing facility that will encompass more than 160,000 square feet at the new biopharmaceutical manufacturing site operated by FUJIFILM in Holly Springs, North Carolina.
This strategic decision entails a significant financial commitment of $2 billion over the next ten years, aimed not only at enhancing the company’s manufacturing capabilities in the U.S. but also at creating approximately 120 new employment opportunities for residents of North Carolina.
In addition to this facility, Johnson & Johnson indicates that it will soon unveil plans for further advanced manufacturing sites across the United States. The company is also looking to expand operations at its existing facilities. These moves illustrate Johnson & Johnson’s commitment to maintaining its leadership position in the healthcare sector by delivering cutting-edge solutions. This strategy will enable Johnson & Johnson to produce the majority of its advanced therapeutic medications within the United States, thereby better addressing the needs of patients domestically.
Earlier this year, in March, the company announced an ambitious investment plan of $55 billion aimed at fortifying U.S. manufacturing, enhancing research and development capabilities, and advancing technology initiatives over the next four years. This investment is expected to have a significant impact on the healthcare landscape, creating numerous job opportunities.
Progress is well underway at the construction site of the new facility in Wilson, North Carolina, which is anticipated to employ over 500 people once it becomes fully operational. Additionally, the construction phase of this site is expected to generate approximately 5,000 temporary jobs, which will significantly contribute to the local economy during the development period.
Johnson & Johnson is committed to investing in robust research and development infrastructure targeted at creating lifesaving and transformative treatments in critical medical fields. These areas include oncology, neuroscience, immunology, and cardiovascular disease, as well as advancements in robotic surgery technology.
By utilizing the FUJIFILM facility in Holly Springs, Johnson & Johnson will significantly enhance its national manufacturing capacity. The company’s comprehensive investment strategy is projected to support thousands of jobs nationwide, positively impacting the economy and improving health outcomes for U.S. patients.
KEY QUOTES:
“Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here. With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”
Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson
